不同剂量乙肝疫苗阻断乙型肝炎病毒母婴传播的远期效果观察

本文对出生后接种不同剂量乙肝血源疫苗的２７２名婴儿进行了３－５年的效果随访观察。结果表明,接种３、４、５年后,抗－ＨＢｓ阳性率仍分别保持在９０．５％、８２．３％和７３．２％,ＨＢｓＡｇ阳性率分别为２．８％、３．１％和４．２％。３年后抗－ＨＢｓ阳性率逐年下降,Ｐ／Ｎ值＞５０者以接种后３年为多,＜５０者以５年为多,３年后也呈下降趋势。随访结果说明,接种１０μｇ×４、５μｇ×４及２．５μｇ×４剂量的乙肝疫苗具有阻断母婴乙肝病毒传播的效果。鉴于Ｐ／Ｎ值及抗－ＨＢｓ阳性率在接种后３年开始下降,建议接种后３年应进行一次加强接种。     

多肽抗体谱免疫印迹法检测ENA抗体的临床应用

本文报道应用多肽抗体谱印迹法检测风湿性疾病患者的ＥＮＡ抗体,该法一次可检测７种抗体。应用本法检测ＳＬＥ８５例,其Ｓｍ抗体阳性率为２０．０％,ｕ１－ＲＮＰ抗体为４１．１％,ＳＳ－Ａ抗体为１０．５％ＳＳ－Ｂ抗体为３．５％,抗核糖体为７．０％。检测ＤＬＥ６例,其山ｕ１－ＲＮＰ抗体阳性率为３３．０％。检测ＰＭ／ＤＭ１５例,其ｕ１－ＲＮＰ抗体阳性率为１３．０％,Ｊｏ－１抗体为１４．０％。检测ＲＡ４８例,其ｕ１－ＲＮＰ抗体的阳性率为３３．３％。检测ＳＳ２１例,其ＳＳ－Ａ抗体阳性率为４３．０％,ＳＳ－Ｂ抗体为３８．０％,检测ＰＳＳ９例,其Ｓｃｌ－７０抗体阳性率为２２．０％。检测ＭＣＴＤ１０例,其ｕ１－ＲＮＰ抗体阳性率为５０．０％。健康人对照１００例,７种抗体均为阴性。显示应用多肽抗体谱印迹法检测结果与国内其它方法所测得结果基本一致,但可检测的抗体种类多于其它方法。     

丙肝病毒非结构基因NS_4的基因工程表达

丙肝病毒非结构基因ＮＳ_４的基因工程表达祁自柏,谷金莲,李河民（中国药品生物制品检定所,北京１０００５０）丙肝病毒（ＨＣＶ）基因由结构区和非结构区（ＮＳ１－５）所组成。抗不同病毒蛋白抗体的出现与丙肝发病的关系尚在研究之中。目前,国内丙肝诊断试剂力求包...     

新型HCV EIA诊断试剂盒的研制

丙型肝炎病毒（ＨＣＶ）基因组结构区核壳蛋白（Ｃ）区抗原、膜蛋白Ｅ１和Ｅ２区抗原,以及非结构区ＮＳ３－ＮＳ５区抗原的区段,已经在原核细胞中获得有效的表达。同时,相应区段中的优势抗原表位肽也经化学合成法大规模地制备。ＨＣＶ基因组上各区段抗原性的分析发现,由Ｃ区和ＮＳ３区分别编码的Ｃ抗原和Ｃ３３ｃ抗原是ＨＣＶ基因组上两个优势抗原区段。其相应的抗体出现早（感染后６周可检出抗Ｃ３３ｃ抗体）,阳转率高（约９９％阳性检出率）,特异性和重复性均优于其它区段抗原。以中国人ＨＣＶ的Ｃ３３ｃ重组蛋白和分支状合成肽ＭＡＰ－Ｃ－１９为复合抗原,研制了适合我国抗ＨＣＶ抗体检测的新型丙型肝炎病毒酶免疫测定（ＨＣＶＥＬＡ）诊断试剂盒。它同当代美国Ａｂｂｏｔｔ／ＵＢＩＨＣＶＥＬＡ诊断试剂的符合率约９８％,同加拿大ＹＥＳ公司ＨＣＶＥＩＡ诊断试剂的符合率约９７．８％,阳性检出率提高了约２％,３次重复性达１００％,表明其特异性、敏感性和重复性均达到了当代第二代ＪＣＶＥＬＡ诊断试剂的水平。我国人群中抗ＨＣＶ抗体的分布情况为：正常人群的检出率１％－２％;外科类住院病人检出率约２８．８％;肝炎患者抗ＨＣＶ阳性率为３４．４％,慢活肝、肝硬化和重症肝炎患者     

新生儿接种小剂量乙肝疫苗后3-5年随访观察

本文对９３８例初生婴儿接种小剂量（１０ｕｇ×３）乙肝疫苗后３－５年的预防效果进行了随访观察,并以２５３例初生儿未接种疫苗者作为对照,结果表明,接种组３－５年后抗－ＨＢｓ阳性率显著高于对照组,ＨＢｓＡｇ阳性率则较对照组显著为低。感染保护率８６．７％。结果还表明,接种乙肝疫苗３年后加强１次,比不加强者Ｐ／Ｎ均值显著增高。文章认为初生儿接种小剂量乙肝疫苗有长期免疫效果;接种后３年加强接种１次,可保持较高免疫力。     

宫粉郁金的组织培养和快速繁殖

１植物名称宫粉郁金（Ｃｕｒｃｕｍａ　ｋｗａｎｇｓｉｅｎｓｉｓ）。２材料类别　块茎萌动芽。３培养条件　萌动芽生长培养基：（１）ＭＳ＋６－ＢＡ１ｍｇ·Ｌ－１（单位下同）＋ＮＡＡ０．２。不定芽增殖与愈伤组织诱导培养基：（２）ＭＳ＋６－ＢＡ１０＋ＫＴ５;（３）ＭＳ＋６．ＢＡ１０;（４）ＭＳ＋６－ＢＡ５＋ＫＴ２．５;（５）ＭＳ＋６－ＢＡ５;（６）ＭＳ＋６－ＢＡ２＋ＫＴ１。生根培养基：（７）ＭＳ＋ＮＡＡ０．５;（８）ＭＳ＋６－ＢＡ０．５＋ＮＡＡ０．５;（９）ＭＳ。以上培养基均加０．７％琼脂,３％蔗糖,ｐＨ５…     

NA和5－HT对小脑脑片浦肯野细胞自发及诱发电活动的影响

在大鼠小脑脑片上观察了ＮＡ和５－ＨＴ对浦肯野细胞（ＰＣ）的自发放电活动及由白质刺激所引起的诱发放电活动的影响。结果表明：（１）ＮＡ使ＰＣ产生抑制、兴奋和双相反应,以抑制反应为主（７９．８％）;５－ＨＴ引起ＰＣ兴奋和抑制反应,以兴奋反应略多（５７．８％）。（２）先后灌流ＮＡ和５－ＨＴ对同一个ＰＣ自发放电的影响主要为抑制（ＮＡ）－兴奋（５－ＨＴ）（５３．８％）。（３）ＮＡ对ＰＣ的诱发复杂锋电位（ＣＳ）和简单锋电位（ＳＳ）反应,主要产生增强效应（５７．１％和６２．８％）;５－ＨＴ对ＰＣ诱发ＣＳ和ＳＳ反应则主要产生压抑作用（６０．０％和６８．２％）。（４）先后灌流ＮＡ和５－ＨＴ对同一个ＰＣ的诱发ＣＳ和ＳＳ反应,主要表现为ＮＡ对这两种诱发反应的增强和５－ＨＴ的压抑效应（６０．０％和５２．９％）。这些结果提示,ＮＡ能和５－ＨＴ能传入纤维可以通过释放ＮＡ和５－ＨＴ调节ＰＣ的兴奋性水平并改变ＰＣ对爬行纤维和苦状纤维突触传入的反应敏感性,影响小脑皮层神经元网络的感觉运动整合过程。     

人原发性肝内胆管细胞癌中HCV RNA及其NS3区抗原的分布及意义

应用原位分子杂交及免疫组分方法,使用地高辛标记ＨＣＶ５’非编码区探针及抗ＨＣＶ ＮＳ３区Ｃ３３ｃ单克隆抗体,对３５例人原发性肝内胆管细胞癌（ＰＩＣ）和癌旁肝组织的ＨＣＶ ＲＮＡ及其ＮＳ３抗原进行检测结果发现ＨＣＶ ＲＮＡ在ＰＩＣ中的阳性率为８３％,ＨＣＶ ＲＮＡ定位于癌细胞浆中,个别病例并在淋巴细胞、肝窦内皮细胞和枯否氏细胞中发现阳性信号。ＨＣＶ ＮＳ３区Ｃ３３ｃ抗原在ＰＩＣ的阳性率为８９％,阳性     

安徽省不同人群及各型肝炎患者庚型肝炎病毒感染检测分析

应用酶联免疫试验（ＥＩＡ）和逆转录套式聚合酶链反应（ＲＴ－ｎＰＣＲ）对１００ 例一般人群、３８５例献血员、５４ 例血液透析患者、７２ 例乙型肝炎、４１ 例丙型肝炎２７ 例非甲－戊型肝炎患者进行检测。结果抗－ＨＧＶ 阳性率分别为２．００％ 、７．５３％ 、２７．７８％ 、１８．０６％ 、１９．５１％ 和１４．８１％ ;抗－ＨＧＶ 阳性者中ＨＧＶＲＮＡ 阳性率分别为１００．００％ 、６２．０７％ 、６６．６７％ 、６９．２３％ 、７５．００％ 和 １００．００％ ,提示本地区不同人群存在ＨＧＶ 感染。献血员、血透患者、乙型肝炎、丙型肝炎、非甲－戊型肝炎患者的ＨＧＶ 感染率显著高于一般人群,提示献血员,血透患者及ＨＢＶ、ＨＣＶ 感染者是ＨＧＶ 感染的高危人群。ＨＧＶ 常与ＨＢＶ 或ＨＣＶ 重叠／联合感染,也可单独感染。抗－ＨＧＶ 阳性者中ＨＧＶ ＲＮＡ 阳性率为８３．８２％ ,提示抗－ＨＧＶＥＩＡ 可用于ＨＧＶ 感染的检测。ＡＬＴ 正常和异常献血员中抗－ＨＧＶ 阳性率无显著性差异。     

用核酸免疫技术制备抗丙肝病毒C区单克隆抗体

用丙肝病毒Ｃ＋Ｅ１区真核表达质粒ｐｃＤＮＡ－ＨＣＶ／Ｃ＋Ｅ１按４００ｕｇ／只剂量免疫ＢＡＬＢ／Ｃ小鼠,１４周后同一剂量再加强免疫一次。加强免疫后２周,在５０％ＰＥＧ１４５０介导下将脾细胞与ＳＰ２／０小鼠骨髓瘤细胞（５１）融合。实验结果融合率达５４．３％（３１３／５７６）。阳性率为５．４％（１７”３１３）。克隆化后得到６株稳定分泌抗丙肝病毒Ｃ区单克隆抗体杂交瘤细胞株。这６株杂交瘤均产生ＩｇＭ抗体,接种ＢＡＬＢ／Ｃ小鼠后产生腹水的效价为１６４－１３２０（ＥＬＩＳＡ）。     

Hepatitis C

Canada now has an institute to study alternative medicine and seek evidence concerning it. The founder, endocrinologist Wah Jun Tze, says most physicians appreciate that the institute will seek to find evidence for unproven therapies. It recently named a research director, and expects to have protocols for randomized, controlled studies in place by the new year. Herbal remedies are one likely candidate for study.     

Persistence of Hepatitis C Virus Traces after Spontaneous Resolution of Hepatitis C

Hepatitis C virus (HCV) frequently causes chronic hepatitis, while spontaneous recovery from infection is infrequent. Persistence of HCV after self-limited (spontaneous) resolution of hepatitis C was rarely investigated. The current study aimed to assess incidence and robustness of HCV persistence after self-resolved hepatitis C in individuals with normal liver enzymes and undetectable virus by conventional tests. Applying high sensitivity HCV RNA detection approaches, we analyzed plasma and peripheral blood mononuclear cells (PBMC) from individuals with previous hepatitis C infection. Parallel plasma and PBMC from 24 such non-viraemic individuals followed for 0.3–14.4 (mean 6.4) years were examined. Additional samples from 9 of them were obtained 4.5–7.2 (mean 5.9) years later. RNA was extracted from 250 μl plasma and, if HCV negative, from ~5 ml after ultracentrifugation, and from ex vivo stimulated PBMC. PBMC with evidence of HCV replication from 4 individuals were treated with HCV protease inhibitor, telaprevir. HCV RNA was detected in 14/24 (58.3%) plasma and 11/23 (47.8%) PBMC obtained during the first collection. HCV RNA replicative strand was evident in 7/11 (63.6%) PBMC. Overall, 17/24 (70.8%) individuals carried HCV RNA at mean follow-up of 5.9 years. Samples collected 4.5–7.2 years later revealed HCV in 4/9 (44.4%) plasma and 5/9 (55.5%) PBMC, while 4 (80%) of these 5 PBMC demonstrated virus replicative strand. Overall, 6/9 (66.7%) individuals remained viraemic for up to 20.7 (mean 12.7) years. Telaprevir entirely eliminated HCV replication in the PBMC examined. In conclusion, our results indicate that HCV can persist long after spontaneous resolution of hepatitis C at levels undetectable by current testing. An apparently effective host immune response curtailing hepatitis appears insufficient to completely eliminate the virus. The long-term morbidity of asymptomatic HCV carriage should be examined even in individuals who achieve undetectable HCV by standard testing and their need for treatment should be assessed.     

Hepatitis C in India

Hepatitis C is an emerging infection in India and an important pathogen causing liver disease in India. The high risk of chronicity of this blood-borne infection and its association with hepatocellular carcinoma underscores its public health importance. Blood transfusion and unsafe therapeutic interventions by infected needles are two preventable modalities of spread of hepatitis C infection. In addition, risk factor modification by reducing the number of intravenous drug users will help curtail the prevalence of this infection. This review summarizes the extent, nature and implications of this relatively new pathogen in causing disease in India.